Amgen USA Inc. is the U.S. arm of Amgen, a large biopharmaceutical company that develops and sells human therapeutics and biotechnology products. Its filings show it lobbies Congress mainly on patent policy — laws and rules that protect drug and biologic patents — likely to defend its intellectual property rights. It reported about $200,000 across four filings, most recently in January 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
MANUS COONEY
The latest disclosures for this client.
ACG ADVOCACY
Q1ACG ADVOCACY
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
ACG ADVOCACY
ACG ADVOCACY
Q3ACG ADVOCACY
Q2ACG ADVOCACY
Q1